34. SEGMENT REPORTING Operating segments Since 1 January 2023, the Group’s segment reporting has been changed to reflect the Group’s new reporting structure that includes Laboratories (“Labs”) as a separate segment. The results for the comparative period have been restated on the same basis. The Group’s reportable segments comprise: • Hospital and healthcare − Singapore − Malaysia − India − Greater China − Türkiye and Europe − Southeast Asia • IMU Health • Labs • PLife REIT • Others Except for IMU Health, Labs and PLife REIT, the strategic business units offer hospital and healthcare services in different locations, and are managed separately. IMU Health is an educational service provider, Labs is a diagnostic laboratory service provider, while PLife REIT is a real estate investment trust. Others comprises the Group’s corporate office as well as other investment holding entities. For each of the strategic business units, the Group’s Board of Directors reviews internal management reports on at least a quarterly basis. Management monitors the operating results of each of its business units for the purpose of making decisions on resource allocation and performance assessment. Performance is measured based on segment earnings before interest, tax, depreciation, amortisation, exchange differences and other non-operational items (“EBITDA”). Inter-segment pricing is determined on negotiated basis. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Annual Report 2023 199
RkJQdWJsaXNoZXIy NDgzMzc=